Skip to content

Cortisone and QTc-Interval

Influence of Cortisone on QTc-interval

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03082339
Enrollment
105
Registered
2017-03-17
Start date
2017-04-01
Completion date
2020-04-25
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

QTc-interval

Brief summary

Scientific and clinical data report about shortening of QTc-interval in patients treated with cortisone. Peal et al. analyzed chemical suppression of long QT syndrome (Type 2) in an in vivo zebrafish model. Their study revealed that flurandrenolide reproducibly suppressed the long QT phenotype via the glucocorticoid signaling pathway. In contrast to treatment with dexamethasone and testosterone, treatment with pure mineralocorticoid deoxycorticosterone acetate did not suppress long QT phenotype. Knockdown of the glucocorticoid receptor or, conversely, of the androgen receptor showed that flurandrenolide acting through the glucocorticoid receptor shortens ventricular action potentials. The mechanism is distinct from trafficking rescue of the defective zebrafish-ERG channel. The authors discuss that a drug normalizing repolarization would be a novel therapeutic tool in long QT syndrome and conclude that glucocorticoids could be expected to aid in the acute management of patients with long QT syndrome, e.g. in episodes of arrhythmic storm. In addition, corticoid induced normalization of the QT interval is reported in a patient with drug-induced prolongation of the QTc interval. Brostoff et al. report on a patient suffering from mucocutaneous leishmaniasis treated with sodium stibogluconate. During therapy, the QTc interval prolonged and returned to normal within 4 days after starting glucocorticoid therapy with prednisolone 20 mg twice daily. Interrogation of the study: * shortens cortisone the QTc-interval? * how long is the interval until shortening of QTc-interval? * is the effect prolonged? * is the effect dose dependend?

Interventions

Observation of QTc-interval

Sponsors

University of Giessen
CollaboratorOTHER
Asklepios Neurological Clinic Bad Salzhausen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients who underwent therapy with cortisone (\>=40mg/d)

Exclusion criteria

* patients with elevated intracranial pressure * myocardial infarction within the last 6 months * untreated stenosis of the coronary arteries * right bundle branch block * autoimmune disease

Design outcomes

Primary

MeasureTime frameDescription
Duration of QTc-interval1 weekdaily ECG controls and measuring QTc-interval

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026